Cost-Effectiveness of Using High-Sensitivity C-Reactive
Protein to Identify Intermediate- and Low-CardiovascularRisk Individuals for Statin TherapyClinical Perspective
by Keane K. Lee, Lauren E. Cipriano, Douglas K. Owens, Alan S. Go, and Mark A.
Hlatky
Circulation
Volume 122(15):1478-1487
October 12, 2010
Copyright © American Heart Association, Inc. All rights reserved.
Simplified diagram of the decision analysis model.
Keane K. Lee et al. Circulation. 2010;122:1478-1487
Copyright © American Heart Association, Inc. All rights reserved.
Results plotted in the cost-effectiveness plane for the risk category of men with hypertension
only.
Keane K. Lee et al. Circulation. 2010;122:1478-1487
Copyright © American Heart Association, Inc. All rights reserved.
Optimal strategy given a quality-of-life decrement for statin use at a willingness-to-pay threshold
of $50 000/QALY, assuming equal effectiveness of statin therapy across various hs-CRP levels.
Keane K. Lee et al. Circulation. 2010;122:1478-1487
Copyright © American Heart Association, Inc. All rights reserved.
Optimal strategy by statin cost at a willingness-to-pay threshold of $50 000/QALY, assuming
equal effectiveness of statin therapy across various hs-CRP levels.
Keane K. Lee et al. Circulation. 2010;122:1478-1487
Copyright © American Heart Association, Inc. All rights reserved.